Related Experiment Videos
[HEPATITIS B.VACCINATION IMPACT ON ACUTE DISEASE,CHRONIC CARRIERS AND HEPATOCARCINOMA INCIDENCE]
Summary
Hepatitis B vaccination significantly reduces disease incidence, chronic carriers, and liver cancer rates. Immunization programs implemented since 1984 show marked epidemiological improvements globally.
Area of Science:
- Hepatology
- Immunology
- Public Health
Background:
- Hepatitis B virus (HBV) causes acute illness and chronic conditions like liver cancer.
- The hepatitis B vaccine, developed in 1982, led to widespread immunization programs.
- These programs, initiated in 1984, have demonstrated significant epidemiological shifts over 15 years.
Purpose of the Study:
- To review the impact of hepatitis B immunization programs.
- Analysis focused on data from Asia, Africa, Europe (Italy), and Peru since 1984.
Main Methods:
- Literature search in MEDLINE (1980-2000).
- Reviewed references from published papers.
- Analyzed epidemiological data on HBV infection and vaccination outcomes.
Main Results:
- Significant reduction in acute hepatitis B incidence in Italy (63 to 3 cases/100,000).
- Decreased HBsAg carrier rates across populations in Italy, Taiwan, Senegal, and Gambia.
- Reduced HBV infection prevalence in children in Taiwan and Peru.
- Noteworthy decrease in hepatocarcinoma incidence in Taiwanese children (0.70 to 0.36/100,000).
Conclusions:
- Hepatitis B vaccination effectively lowers acute disease incidence.
- Vaccination significantly reduces HBV carrier rates and overall infection prevalence.
- Immunization programs are crucial in decreasing hepatocarcinoma incidence in children.